Replies to post #83625 on Ayala Pharmaceuticals Inc (fka ADXS)

[Batermere]

I think you forgot to add another Public Offering at .50/share to get us through the next year and a possible RS to keep from getting DELISTED. KB is a complete and utter failure. He hasn’t done squat since taking over six months ago. He’s just another worthless blood sucking leech ADXS CEO making over $1 million for running ADXS into the ground.

[raja48185]

Upcoming things to look forward to....

Anticipated Milestones Over the Next 12 Months with
TARGET
ADXS-HPV (axalimogene filolisbac) • Announce planned Investigator Sponsored Trial in Head and Neck Cancer Q4 2018
ADXS-HOT Prostate • IND Submission Q4 2018
ADXS-PSA • MetastaticProstatePh1/2Combinationwithpembrolizumab-- Part B Monotherapy Combination Therapy Data (12-mo PFS and OS) Q1 2019
ADXS-NEO • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT NSCLC • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT Bladder • IND Submission 2019
ADXS-HOT Construct #4 • IND Submission Selected from Breast, ovarian, MSS-CRC, H&N 2019

Show me the money in any of these.

[Tupoofy]

IND submissions and IST trial initiations are money vacuums.
The only key outputs to focus on to see this stock bump up due to results for this coming 12 months are:
ADXS-PSA • MetastaticProstatePh1/2Combinationwithpembrolizumab-- Part B Monotherapy Combination Therapy Data (12-mo PFS and OS) Q1 2019
ADXS-NEO • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT NSCLC • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT Bladder • IND Submission 2019

And the PSA data released at poster session during ASCO 2018 was not objectively impressive.

We can always continue to pray Ken makes a deal though!